Clinical Trial Update: ATG in HLA-matched Sibling HSCT as GVHD Prophylaxis [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating ATG for GVHD prophylaxis in HLA-matched sibling hematopoietic stem cell transplantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematopoietic Stem Cell Transplantation-related Gvhd Prophylaxis Context

Drugs mentioned

• ATG (anti-thymocyte globulin)

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Hematopoietic Stem Cell Transplantation | Phase 4 | Status: UNKNOWN